08:24 AM EDT, 09/19/2025 (MT Newswires) -- Alvotech ( ALVO ) said Friday that its partner Fuji Pharma received approval from Japan's Ministry of Health, Labor and Welfare for three new biosimilars.

The biotech company said AVT03, AVT05 and AVT06 were approved for the Japanese market. AVT03 is a biosimilar to Ranmark and has been approved in Japan for the treatment of bone lesions caused by multiple myeloma or metastases of solid tumors, Alvotech ( ALVO ) said.

AVT05 is a biosimilar to Simponi, approved for treating rheumatoid arthritis in patients who have not responded adequately to conventional treatments, the company said.

Alvotech ( ALVO ) also said that AVT06, a biosimilar to Eylea, was approved for treating eye conditions, including age-related macular degeneration and macular edema.